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Angiotensin-(1-7) [Ang-(1-7)] was originally thought to be an inactive metabolite of angiotensin II (Ang II) in the renin angiotensin system (RAS). However, reported biological effects and seminal discoveries of an angiotensin converting enzyme (ACE) homologue, ACE2 which metabolises Ang II to Ang-(1-7), 1 the receptor leading to AT 1 R internalisation, -arrestin-dependent signalling and potential therapeutic outcomes which are distinct to the classical G protein-coupled responses. 8 Galandrin et al performed a systematic evaluation of angiotensin peptides was performed in AT 1 R-overexpressing HEK293T cells. Biased AT 1 R agonism is being actively investigated for therapeutic applications. The classical actions of Ang II at the AT 1 R in hypertension and cardiovascular disease (CVD) are mainly mediated through activating G q . Conversely, AT 1 R signalling also leads to non-G protein-mediated signalling through -arrestin2 which is therapeutic in CVD. Currently, the -arrestin2-biased AT 1 R molecule TRV1200027 is being explored in clinical trials for heart failure after demonstrating efficacy in reducing blood pressure and improving cardiac function in rodent models. 9 The therapeutic development of biased AT 1 R agonists is important in the context of Ang-(1-7) as a biased AT 1 (1-7) and other RAS receptors, with effects reported via the AT 2 R 10 and MrgD. 4 However, AT 2 R studies have predominantly utilised the AT 2 R antagonist PD-123,319 which is also reported to inhibit MrgD which may complicate interpretation. 3, 4 Furthermore, Mas is also a physiological antagonist of the AT 1 R, again highlighting the complexity of cross-talk in the RAS. 11 These new studies 7 are the first demonstration that Ang-(1-7) can both interact with the AT 1 R and mediate distinct signalling effects and provide new knowledge regarding how RAS components interact via crosstalk.
What remains to be dissected is how these individual peptide/ receptor interactions function in vivo. In a diseased tissue there are likely to be differing levels of RAS-related receptors and dynamically changing angiotensin peptide levels and it will be difficult to determine the relative contribution of individual peptides acting at different receptors. Nevertheless it will be important to research the contribution of biased agonism from Ang-(1-7) at the AT 1 R and integrate the knowledge with that known through Mas agonism.
In summary, this study 7 has defined novel interactions in the RAS and contributes to increased knowledge of how RAS peptides and receptors intersect to mediate biological outcomes. Further understanding of these aspects of the RAS may lead to the next generation 4 of RAS-targeting medicines capable of integrating differential signalling outcomes into synergistic action in CVD.
Sources of funding
Work on the renin angiotensin system in the author's laboratory is supported by the Medical
Research Council (MR/L019108/1).
Disclosure statement
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